Structural characterisation of the co-inhibitory complex formed by the tumour suppressor PTEN and the metastatic factor PREX2 [ 2018 - ]

Research Grant

Researchers: Dr Andrew Ellisdon (Principal investigator) ,  A/Pr Hans Elmlund ,  Dr Michelle Halls

Brief description Metastasis is a major cause of cancer mortality. Characterisation of key proteins that regulate metastasis is therefore a priority. PTEN and PREX2 are enzymes that play key roles in metastasis in melanoma, and other cancers. We will determine the structural basis of PTEN:PREX2 co-inhibition, and determine how cancer-associated PREX2 mutations dysregulate this inhibitory complex. This study will provide the necessary knowledge for future drug development programs targeting PTEN:PREX2 in cancer.

Funding Amount $555,821.00

Funding Scheme Project Grants

Notes Standard Project Grant